Loading...

PODCAST

The Uromigos

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew"s Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

health & fitness medicine

All Episodes

00:33:24

Episode 519: What is the Appropriate Approach to...

The Uromigos ·

2026/10/05

Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).

en

00:31:08

Episode 518: PSMAddition in Clinical Practice

The Uromigos ·

2026/09/28

Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk

en

00:40:53

Episode 517: Casdatifan Clinical Data in RCC and...

The Uromigos ·

2026/08/31

Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.

en

00:47:50

Episode 516: The Influence of Hypoxia on Response and...

The Uromigos ·

2026/08/17

Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.

en

00:43:06

Episode 515: PROTEUS - A Reflection on the Data and...

The Uromigos ·

2026/08/03

Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

en

00:40:24

Episode 514: Artificial Intelligence in Cancer Drug...

The Uromigos ·

2026/07/20

Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

en

00:25:34

Episode 513: Trials and Tribulations of...

The Uromigos ·

2026/07/13

Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.

en

00:31:12

Episode 512: ENZA-P Nature Medicine translational data

The Uromigos ·

2026/07/06

In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.

en

00:30:23

Episode 510: ADCs in Prostate Cancer

The Uromigos ·

2026/06/15

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

en

00:55:12

Episode 509: ASCO 2026 Review

The Uromigos ·

2026/06/08

This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.

en

00:39:40

Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/-...

The Uromigos ·

2026/05/31

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

en

00:41:45

Episode 507: ASCO 2026 - TALAPRO-3

The Uromigos ·

2026/05/30

Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

en

00:19:46

Episode 506: ASCO 2026 - How do we measure quality of...

The Uromigos ·

2026/05/30

This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centered metrics.

en

00:29:31

Episode 505 : ASCO 2026 - RAMPART

The Uromigos ·

2026/05/30

James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

en

00:40:32

Episode 504: ASCO 2026 - ADC Drug Development in...

The Uromigos ·

2026/05/29

This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

en

00:37:18

Episode 499: APCCC 2026 - Radioligands in Prostate...

The Uromigos ·

2026/05/25

This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.

en

01:22:10

Episode 503: ASCO 2026 Preview

The Uromigos ·

2026/05/22

Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026

en

00:35:16

Episode 502: AUA 2026 and FDA bladder cancer meeting

The Uromigos ·

2026/05/20

In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies

en

00:19:39

Episode 501: APCCC 2026 - Biochemically-relapsed...

The Uromigos ·

2026/05/18

Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.

en

00:35:16

Episode 500: RAS Inhibition in Pancreatic Cancer (yes...

The Uromigos ·

2026/05/11

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

en

521 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

To Birth and Beyond

Anita Lambert & Jessie Mundell

The Fitness League

Alessandra and Josh Scutnik, Joelle...